

Application of semiparametric model in modelling diabetic retinopathy among type II diabetic patients

Bezalem Eshetu Yirdaw (✉ 12962805@mylife.unisa.ac.za)

University of South Africa

Legesse Kassa Debusho

University of South Africa

Research Article

Keywords: Covariate by factor interaction, diabetes mellitus, diabetic retinopathy, semiparametric model, tensor product interaction

Posted Date: April 13th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1532336/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

RESEARCH

Application of semiparametric model in modelling diabetic retinopathy among type II diabetic patients

Bezalem Eshetu Yirdaw^{1*} and Legesse Kassa Debusho²

*Correspondence:

12962805@mylife.unisa.ac.za

¹Department of Statistics,

University of South Africa c/o

Christiaan de Wet Road & Pioneer

Avenue, Florida 1709,

Johannesburg, South Africa

Full list of author information is

available at the end of the article

Abstract

Background: The proportion of patients with diabetic retinopathy (DR) has grown with increasing number of diabetic mellitus patients in the world. It is among the top risk factors of blindness worldwide, especially those living in developing countries. The main objective of this study was to identify contributing risk factors of diabetic retinopathy among type II diabetic patients.

Method: A sample of 191 type II diabetic patients was selected from the Black Lion Specialized Hospital diabetic unit from 1 March 2018 to 1 April 2018. A multivariate stochastic regression imputation technique was applied to impute the missing values. The response variable, diabetic retinopathy is a categorical variable with two outcomes. Based on the relationship derived from the exploratory analysis, the odds of diabetic retinopathy were not necessarily linearly related to the continuous predictors for this sample of patients. Therefore, a semiparametric model was proposed to identify the contributing factors of diabetic retinopathy.

Result: From the sample of 191 type II diabetic patients, 98(51.3%) of them experienced diabetic retinopathy. The results of semiparametric regression model revealed that gender, hypertension, insulin treatment, and frequency of clinical visits had a significant linear relationships with the odds of diabetic retinopathy. In addition, the log- odds of DR has a significant nonlinear relation with the interaction of age by gender (for female patients), duration of diabetes, interaction of cholesterol level by gender (for female patients), haemoglobin A1c, and interaction of haemoglobin A1c by fasting blood glucose with degrees of freedom 3.2, 2.7, 3.6, 2.3 and 3.7, respectively. The interaction of age by gender and cholesterol level by gender appear non significant for male patients. The result from the interaction of haemoglobin A1c (HbA1c) by fasting blood glucose (FBG) showed that the risk of diabetic retinopathy is high when the level of HbA1c and FBG were simultaneously high.

Conclusion: Clinical variables related to type II diabetic patients were strong predictive factors of diabetic retinopathy. Hence, health professionals should be cautious about the possible effects and complications of diabetic mellitus which can be caused by the clinical variables. Furthermore, to improve intervention strategies similar studies should be conducted across the country.

Keywords: Covariate by factor interaction; diabetes mellitus; diabetic retinopathy; semiparametric model; tensor product interaction

3 Introduction

4 Diabetes mellitus (DM) is one of the major noncontagious diseases that has a cumulative consequence on people in both developed and developing countries [1].
5 International diabetic federation in 2019 has reported that the estimated number
6 of diabetic patients was 463 million, of which 19 million were from Africa including
7 14.2 million in sub-Saharan Africa [2]. Diabetic retinopathy (DR) is one of
8 the microvascular complications of diabetes mellitus which is characterized by the
9 presence of microaneurysms, haemorrhages, exudation, cotton wool spot, and/or
10 new vessels in the peripheral retina, macula, or both [3, 4, 5]. The progression of
11 DR has four stages; mild non-proliferative diabetic retinopathy (NPDR), moderate
12 (NPDR), severe (NPDR), and proliferative diabetic retinopathy (PDR). In the first
13 three stages, the formulation of microaneurysms may leak fluid and block blood
14 vessels in the retina. On the other hand, PDR is the advanced stage which is characterized
15 by the formulation of new blood vessels that can cause more leakage and
16 bleeding of the retina, and can lead to permanent vision loss [6].
17

18 Among the total number of diabetic patients in the world about one third of them
19 develop diabetic retinopathy. Furthermore, it has been the top cause of blindness
20 in the middle age and elderly patients worldwide, of which more than 93 million
21 patients suffer from DR [7]. Out of 10% adult patients worldwide, 7.5% are living in
22 low- and medium-income countries, where healthcare resources are limited [7]. The
23 estimated annual incidence and progression of diabetic-related eye disease ranged
24 from 2.2% to 12.7% and 3.4-12.3%, respectively [5, 8]. Among 1.5 billion blind
25 people in the world, 0.4 million were due to diabetic retinopathy [9]. There was
26 a noticeable reduction in the number of blindness and vision loss in the world.
27 However, the percentage of blindness and moderate to severe vision impairment
28 due to DR increased by approximately 50% and 53%, respectively [9]. Further, the
29 proportion of DR in Africa ranges from 7% to 62.4%, of which severe DR was
30 observed in 15% of the patients. Ethiopia is one among the lower-income countries
31 with a high percentage (3.8%) of adult diabetic community in sub-Saharan Africa
32 [2, 10]. A study reveal that the prevalence of retinopathy among type II diabetic
33 patients and in a group without diabetes was 34.6% and 8.8%, respectively [11].

34 Studies across the world have shown that, the most predictive factors of diabetic
35 retinopathy are socio-demographic and clinical variables such as age, diabetic duration,
36 lipid profiles of a patient and microalbuminuria [5, 12, 13, 14, 15, 16, 17].
37 Hussain et al. [15] reported that, gender and clinical variables have significant relationships
38 with DR. Furthermore, glycaemic control and body-mass index have significant associations
39 with diabetic retinopathy [4, 5]. A study from Ethiopia reported that, gender, haemoglobin a1c
40 (HbA1c) and hypertension are predictive risk factors of diabetic retinopathy [17]. Some studies
41 have also revealed that the odds of diabetic retinopathy is higher for a patient with higher
42 HbA1c [4, 12, 15, 18], longer duration of diabetes [5, 12] and hypertensive patients [4, 5, 17].
43 A study based on data from a meta-analysis of seven cohort studies reported that insulin
44 treatment has significant association with diabetic retinopathy in patients with type
45

46 II diabetes mellitus [13]. Another study based on 5.2 years follow up data indicates
47 that variability of fasting plasma glucose (FPG) is a significant predictor of dia-
48 betic retinopathy [19]. Ten years follow up study also showed that, as compared to
49 patients who did not experience DR, patients who experienced DR had a higher
50 level of FPG and HbA1c [20].

51 At Black Lion Hospital (BLH), Addis Ababa, Ethiopia, health professionals at the
52 diabetic unit are well trained in screening DR. Depending upon the stage of DR
53 that a patient experiences, a clinician also provides appropriate treatment to pre-
54 vent vision loss and blindness. Studies in Ethiopia used a parametric model, e.g.,
55 GLM which only identify the linear relationship between the link function and co-
56 variates to determine predictive factors of DR [5, 14, 17]. However, because of the
57 incorrect functional form of the model some high risk covariates may be interpreted
58 as no relationship with the response. In 2018, a study at BLH used binary logistic
59 regression and identified gender, duration of diabetes, HbA1c, hypertension and
60 frequency of clinical visit as predictors of diabetic retinopathy [17]. However, in this
61 study all continuous predictors except duration of diabetes were categorized and
62 considered as factors, and linear association between the response and predictors
63 were considered via the logit link. For the current study, we used the same data
64 from Shibru, Aga and Boka [17]. However, plots of continuous predictors from ex-
65 ploratory analysis (see Figure 1) shows nonlinearity and a logistic regression model
66 may be too restrictive to analyse this data. Therefore, to develop effective strate-
67 gies for the prevention of diabetic retinopathy, estimating the correct functional
68 form of the model is important. Accordingly, the main aim of this research was to
69 identify the contributing risk factors of diabetic retinopathy among type II diabetic
70 patients at Black Lion Hospital and to estimate the data driven relationship be-
71 tween clinical variables, specifically continuous predictors and diabetic retinopathy
72 using semiparametric models. According to [21], the functional form of a covariate
73 in additive model varies across groups defined by levels of categorical variables.
74 Further, the interaction between age and gender of a diabetic patient is epidemio-
75 logically plausible for consideration [22]. Therefore, this study was also motivated
76 to estimate the functional form of the interaction effect of a covariate by the levels
77 of categorical variables.

78 A study shows that there is a strong connection between HbA1c and FBG in a dia-
79 betic subject [23]. In a different study, it was reported that the interaction between
80 mean HbA1c and FPG variability has no significant association with the odds of
81 diabetic retinopathy [19]. However, Figure 1, which was generated from the current
82 study data reveals each of the potential covariates HbA1c and FBG has a nonlinear
83 relationship with the odds of diabetic retinopathy. This brings a question of what
84 if the interaction of HbA1c and FBG has a significant nonlinear effect on being
85 diabetic retinopathy. Therefore, we have also considered the interaction of HbA1c
86 and FBG.

87 The remaining section of the paper is organized as follows. First, a description of the
88 study data and semiparametric models for a binary response are discussed in the

89 methodology section. In the result section, the findings from applying these models
 90 on the study data are illustrated. Finally, discussion and conclusion with recom-
 91 mendation and pointers for future study are given in the discussion and conclusion
 92 sections, respectively.

93 Methodology

94 Study area and data

95 The data for this study was a secondary data obtained from BLH and the details
 96 on the data are available in [17]. BLH hospital is located at Addis Ababa, Ethiopia
 97 and it is the largest teaching hospital in Ethiopia. The diabetic unit at BLH gives
 98 a service provision for more than 200 individuals per week. For this study, a cross-
 99 sectional study design was used. The data was collected from March to April 2018
 100 and all type II diabetic patients who had a follow up at BLH diabetic unit within
 101 the study period were eligible for this study. The study excludes critically ill pa-
 102 tients who were very weak to give informed consent to participate in the study.
 103 A total of 191 patients were used for the analysis. The response variable, diabetic
 104 retinopathy is a categorical variable with two outcomes which is measured via di-
 105 rect eye examination using Topcon Camera [24]. Socio-demographic and treatment
 106 related variables were collected via face-to-face individual interview, and clinical
 107 variables, such as duration of diabetes since a patient confirmed to type II diabetes,
 108 frequency of clinical visits, fasting blood glucose, cholesterol level, Haemoglobin
 109 A1c and status of hypertension were extracted from patients record. To sum up,
 110 this study includes categorical and continuous variables as predictors of diabetic
 111 retinopathy, where gender, hypertension, insulin treatment, and frequency of clini-
 112 cal visits were considered as factors and age, duration of diabetes, total cholesterol
 113 level, haemoglobin A1c and fasting blood glucose were considered as covariates.

114 *Semiparametric model for binary response*

115 Given the exploratory plots in Figure 1, a semiparametric model is more reasonable
 116 for this data rather than assumptions based restrictive parametric models. Let a
 117 binary outcome variable y_i denotes the diabetic retinopathy status of the i^{th} patient,
 118 where $y_i = 1$ represents patient with diabetic retinopathy and $y_i = 0$ represents
 119 patient without diabetic retinopathy, let z_m denotes the m^{th} categorical variable,
 120 $m = 1, \dots, M$ and let x_j denotes j^{th} continuous variable, $j = 1, \dots, J$ then a
 121 semiparametric model for the outcome y_i is given by:

$$g(\mu_i) = \alpha_0 + \sum_{m=1}^M \sum_{l=1}^{L_m} \alpha_{ml} z_{iml} + h_j(x_{ij}) + f_{z_i}(x_{ij}) + f_{ab}(x_a, x_b), \quad (1)$$

122 where $\mu_i = E(y_i)$, α_0 is the model constant, $\sum_{m=1}^M \alpha_{ml} z_{iml}$ is the parametric term of
 123 the model for the categorical variables (gender, hypertension, insulin treatment and
 124 frequency of clinical visit), z_{iml} is the l^{th} level of m^{th} categorical variable measured
 125 on the i^{th} type II diabetic patients and α_{ml} is the corresponding parameter, M
 126 is total number of categorical variables, L_m is number of categories/level of the
 127 m^{th} categorical variable, $l = 1, \dots, L_m$, e.g., when the m^{th} categorical variable
 128 has two levels, we have one α_{ml} , i.e. $L_m = 1$ because the first category is treated

129 as a reference category. For example, in this study frequency of clinical visit has
 130 three categories (every 1 month, every 3 month and every 6 month), where, every
 131 1 month was treated as a reference category. Additionally, $h_j(x_{ij})$ is a smoothing
 132 function for the continuous clinical predictors, $f_{z_i}(x_{ij})$ is a smoothing function for
 133 the covariate by factor level interaction, x_{ij} is the j^{th} continuous predictor measured
 134 on the i^{th} type II diabetic patients and $f_{ab}(x_a, x_b)$ is a smoothing function for
 135 the tensor product interaction of two continuous clinical variables x_a and x_b . In a
 136 semiparametric model, for each level of a factor we have one curve representing a
 137 covariate by factor interaction. For example, in the current study we have age by
 138 gender interaction which have two separate curves for male and female. To do this
 139 define:

$z_i \in \{1, \dots, L_m\}$ and

$$z_{il} = \begin{cases} 1, & \text{if } z_i = l \\ 0, & \text{else,} \end{cases}$$

140 Thus, the model in Expression (1) can be written as:

$$\begin{aligned} g(\mu_i) &= \alpha_0 + \sum_{m=1}^M \sum_{l=1}^{L_m} \alpha_{ml} z_{ilm} + \beta_{1j} x_{ij} + \beta_{2j} x_{ij}^2 + \dots + \beta_{pj} x_{ij}^p \\ &+ \sum_{k=1}^K b_{kj} (x_{ij} - \kappa_{kj})_+^p \\ &+ \sum_{l=2}^{L_m} z_{il} (\gamma_{0l} + \gamma_{1lj} x_{ij} + \gamma_{2lj} x_{ij}^2 + \dots + \gamma_{plj} x_{ij}^p) \\ &+ \sum_{l=1}^{L_m} z_{il} \left\{ \sum_{k=1}^K c_{kj}^l (x_{ij} - \kappa_{kj})_+ + f_{ab}(x_a, x_b) \right\} \end{aligned} \quad (2)$$

$$f_{ab}(x_a, x_b) = \sum_{s_1=0}^p \sum_{s_2=0}^p \delta_{s_1 s_2} x_{ia}^{s_1} x_{ib}^{s_2} + \sum_{k_1=1}^{K_1} \sum_{k_2=1}^{K_2} b_{k_1 k_2} (x_{ia} x_{ib} - \kappa_{k_1 k_2})_+^p,$$

141 $w_+ = \max\{0, w\}$, $\beta_{1j}, \beta_{2j}, \dots, \beta_{pj}$ are fixed effect parameters for the main ef-
 142 fect smoothing functions, $(\gamma_{0l}, \gamma_{1lj}, \dots, \gamma_{plj})$ are fixed effect parameters for the
 143 smoothing function of an interaction of x_j by L_m levels of a factor z_i , x_{ia} and
 144 x_{ib} are two continuous predictors measured on the i^{th} type II diabetic patients
 145 which are considered to have a tensor product interaction effect on the response,
 146 $\sum_{s_1=0}^p \sum_{s_2=0}^p \delta_{s_1 s_2}$ are fixed effect parameters for the tensor product smoothing
 147 interaction $x_a \odot x_b$. Finally, κ_{kj} are knots where the p^{th} degree spline evaluated
 148 at a covariate x_j and covariate by factor interaction of the smoothing term, and
 149 $\kappa_{k_1 k_2}$ are knots where the p^{th} degree spline evaluated at the tensor product $x_a \odot x_b$
 150 for the tensor product interaction of the smoothing term, $\sum_{k=1}^K b_{kj} (x_{ij} - \kappa_{kj})_+^p$ is
 151 the over all smooth term for the main effect, $\sum_{l=1}^{L_m} z_{il} \left\{ \sum_{k=1}^K c_{kj}^l (x_{ij} - \kappa_{kj})_+ \right\}$ is
 152 the deviation from the over all smooth term of the covariate by factor interaction
 153 and $\sum_{k_1=1}^{K_1} \sum_{k_2=1}^{K_2} b_{k_1 k_2} (x_{ia} x_{ib} - \kappa_{k_1 k_2})_+^p$ is the overall smooth term for the tensor
 154 product smoothing function. According to [25], a Penalized cubic regression spline
 155 allows to retain the good properties of splines and has good computational effi-
 156 ciency. Therefore, we have considered a penalized cubic regression spline ($p = 3$) to
 157 model nonlinearity of the covariates. The respective random effect coefficients b_{kj} ,
 158 c_{kj}^l and $b_{k_1 k_2}$ were assumed to follow a gaussian distribution, i.e. $b_{kj} \sim N(0, \sigma_{b_j}^2)$,
 159 $c_{kj}^l \sim N(0, \sigma_{cl}^2)$ and $b_{k_1 k_2} \sim N(0, \sigma_{b_{ab}}^2)$, respectively.

160 *Proposed semiparametric models*

161 The locally estimated scatter-plots smoothing presented in Figure 1 suggest that
 162 the relationship between the log odds of being DR and each of the continuous
 163 clinical variables is nonlinear. Moreover, Figure 3 revealed that there is a variation
 164 between the total cholesterol levels of male and female. Therefore, it is worthy to
 165 investigate the interactions of age by gender and HbA1c by FBG ($HbA1c \times FBG$).
 166 Thus, we proposed five different semiparametric models. We start with a more
 167 general model (M_1) which includes gender, hypertension, frequency of clinical visit
 168 (FCV) and insulin treatment (IT) as a linear term and interactions of age by gender,
 169 $HbA1c \times FBG$, total cholesterol level (CL) by gender, and duration of diabetes (DD)
 170 as nonlinear terms and M_1 therefore defined as

$$\begin{aligned} g(\mu_i) &= \beta_0 + \beta_1 \text{gender} + \beta_2 \text{hypertension} + \beta_3 IT \\ &+ \beta_4 FCV + f_{\text{gender}}(\text{age}) + f(DD) + f(HbA1c) \\ &+ f(FBG) + f(HbA1c, FBG) + f_{\text{gender}}(CL) \end{aligned} \quad (3)$$

171 where, using Expression (2) presentation, for example

$$f(DD_i) = \beta_0 + \beta_1(DD_i) + \beta_2(DD_i)^2 + \dots + \beta_p(DD_i)^p + \sum_{k=1}^K b_k((DD_i) - \kappa_k)_+^p$$

172 and

$$\begin{aligned} f(HbA1c_i, FBG_i) &= \sum_{s_1=0}^p \sum_{s_2=0}^p \delta_{s_1 s_2} (HbA1c_i)^{s_1} (FBG_i)^{s_2} \\ &+ \sum_{k_1=1}^{K_1} \sum_{k_2=1}^{K_2} b_{k_1 k_2} ((HbA1c_i)(FBG_i) - \kappa_{k_1 k_2})_+^p. \end{aligned}$$

173 The second model M_2 was proposed to test the nonlinearity of $HbA1c \times FBG$ and
 174 it is given by

$$\begin{aligned} g(\mu_i) &= \beta_0 + \beta_1 \text{gender} + \beta_2 \text{hypertension} + \beta_3 IT \\ &+ \beta_4 FCV + \beta_5 HbA1c + \beta_6 FBG + \beta_7 HbA1c \times FBG \\ &+ f_{\text{gender}}(\text{age}) + f(DD) + f_{\text{gender}}(CL) \end{aligned} \quad (4)$$

The third model M_3 was proposed to test the nonlinearity of age by gender inter-
 action and it is given by

$$\begin{aligned} g(\mu_i) &= \beta_0 + \beta_1 \text{gender} + \beta_2 \text{age} + \beta_3 \text{age} \times \text{gender} \\ &+ \beta_4 \text{hypertension} + \beta_5 IT + \beta_6 FCV \\ &+ f(DD) + f(HbA1c, FBG) + f_{\text{gender}}(CL) \end{aligned} \quad (5)$$

175 The fourth model M_4 was proposed to test the nonlinearity of total cholesterol level
 176 by gender interaction and it is given by

$$\begin{aligned}
g(\mu_i) &= \beta_0 + \beta_1 \textit{gender} + \beta_2 \textit{CL} + \beta_3 \textit{CL} \times \textit{gender} \\
&+ \beta_4 \textit{hypertension} + \beta_5 \textit{IT} + \beta_6 \textit{FCV} \\
&+ f_{\textit{gender}}(\textit{age}) + f(\textit{DD}) + f(\textit{HbA1c}, \textit{FBG})
\end{aligned} \tag{6}$$

The fifth model M_5 was proposed to test the nonlinearity of duration of diabetes and it is given by

$$\begin{aligned}
g(\mu_i) &= \beta_0 + \beta_1 \textit{gender} + \beta_2 \textit{hypertension} \\
&+ \beta_3 \textit{IT} + \beta_4 \textit{FCV} + \beta_5 \textit{DD} + f_{\textit{gender}}(\textit{age}) \\
&+ f(\textit{HbA1c}, \textit{FBG}) + f_{\textit{gender}}(\textit{CL})
\end{aligned} \tag{7}$$

177 *Estimation of parameters*

178 Estimation of both penalized and unpenalized coefficients in the above models was
179 done using penalized iterative reweighted least squares (PIRLS). We have used
180 evenly spaced knots with $k = 10$ in the ranges of the covariate x_j for main effect
181 and for covariate by factor interaction of the smoothing functions, and $k = 8$ for
182 the tensor product interaction [25]. Since under finite sample size, prediction error
183 criteria, such as generalized cross validation (GCV) (for the known scale parameter)
184 and unbiased risk estimator (UBRE) (for the unknown scale parameter), is more
185 likely to develop multiple minima which undersmooth the function f_j relative to
186 restricted maximum likelihood (REML), therefore the smoothing parameter selec-
187 tion in the analyses was done using REML and data analysis was done using `gam`
188 function from `mgcv` package in R statistical software. For the detailed information
189 on parametric estimation and modeling of semiparametric model see [25] and for
190 covariate by factor interaction of a smoothing function see [21].

191 *Test of nonlinearity*

192 The hypothesis test for a statistically significance of a nonlinear effect of a continu-
193 ous covariate x_j was done using the likelihood ratio test by fitting two models, that
194 is, we fit first a model where x_j has a linear relationship and then a second model
195 with a nonlinear relationship. Then the hypothesis is, there is a linear relationship
196 between the covariate x_j and the response against there is no linear relationship
197 between the covariate x_j and the response.

198 **Results**

199 *Missing data imputation*

200 The presence of missing observations in some of the variables in a data has an effect
201 on statistical inference, such as poor precision on confidence intervals and biased
202 on parameter estimates, which may result poor statistical power [26]. Therefore, we
203 imputed the missing values of variables with more than 5% missing values using
204 multivariate stochastic regression imputation technique [27]. Furthermore, missing
205 observations in two variables, cholesterol level and HbA1c which had 9% and 50%
206 missing values, respectively were imputed using the above technique. As it can be
207 seen in Figure 2, the distribution for the imputed values and observed values are
208 similar.

209 *Descriptive statistics*

210 There were a total of 191 type II diabetic patients in the study, of which 98 (51.3%)
211 experienced diabetic retinopathy. Among the total sample, 114 (59.7%) were fe-
212 male, of which 51 (26.7%) of them experienced diabetic retinopathy. More than half
213 (54.8%) of the total patients in the study were hypertensive, of which 76 (39.8%)
214 of them experienced diabetic retinopathy. Out of patients who used insulin treat-
215 ment, 40 (20.9%) of them experienced diabetic retinopathy. The total number of
216 patients whose clinical visit was within 1 month interval was 43 (22.6%), of which
217 7.4% of them experienced diabetic retinopathy. Moreover, of those patients whose
218 clinical visit were within 3 and 6 months interval, 38 (20%) and 46 (24.2%) of them
219 experienced diabetic retinopathy, respectively. The mean age of patients who experi-
220 enced diabetic retinopathy was 58.5 years with a standard deviation of 10.1 years
221 (Table 1). The average diabetic duration since a patient was confirmed to type II
222 diabetes mellitus till the patient experienced diabetic retinopathy was 15.2 years
223 with a standard deviation of 10.9 years. In this study, HbA1c is measured in per-
224 centage form known as Diabetes Control and Complications Trial (DCCT) units.
225 The mean HbA1c for a patient with diabetic retinopathy was 9.3% with a standard
226 deviation of 2.8%. In addition, the average total cholesterol level for a patient who
227 experienced diabetic retinopathy was 187.6 mg/dL. The mean FBG for a patient
228 who experience diabetic retinopathy was 170.9 mg/dL with a standard deviation of
229 66 mg/dL (Table 1).

230 As it can be seen from the box plot in Figure 3, the median total cholesterol level for
231 female was around 186 mmol/L and the median cholesterol level for male patient
232 was around 171 mmol/L.

233 *Test of multicollinearity and nonlinearity*

234 The covariates were checked for multicollinearity using the variance inflation factor
235 (VIF) before adding them to the model. None of these VIFs (the values are be-
236 tween 1.08 and 1.21) were greater than 5 suggesting the collinearity is not strong
237 to affect the statistical inference in the analysis. Next, the five proposed models
238 in the methodology section were fitted and a likelihood ratio test was used to test
239 the nonlinearity of continuous covariates. As it can be seen from Table 2, the de-
240 viance for testing the nonlinearity of the interaction of age by gender is 11.98 with
241 $p - value = 0.0461$, indicating that there was a significant nonlinear relationship
242 between the odds of diabetic retinopathy and the interaction of age by gender. Sim-
243 ilarly, the deviance for the nonlinearity test of cholesterol level by gender is 37.20
244 with $p - value = 0.0012$. Thus, there was a significant nonlinear relationship between
245 the odds of diabetic retinopathy and the interaction of cholesterol level by gender.
246 The likelihood ratio test for the relationship between the odds of diabetic retinopa-
247 thy and duration of diabetes has deviance equals to 13.02 with $p - value = 0.0228$
248 (Table 2), therefore, the relationship was significantly nonlinear. The nonlinearity
249 test for the interaction of HbA1c and FBG was also significant ($p - value = 0.0157$)
250 supporting the nonlinear relationship.

251 *Model selection*

252 In this section, we are focusing in selecting the best model which fits the data very
253 well using Akaike's Information Criterion (AIC). As it can be seen from Table 3, M_1
254 is a model with the smallest AIC value (163.64) which supports the nonlinearity test
255 in Table 2. Therefore, the final model which best explains the diabetic retinopathy
256 data for a patient at Black Lion Hospital during the study period was M_1 which
257 includes gender, hypertension, insulin treatment and frequency of clinical visit as
258 a linear term and the interaction of age by gender, duration of diabetes, tensor
259 product or interaction of HbA1c and FBG, and cholesterol level by gender as smooth
260 functions with the cubic spline bases. Therefore, the result in the next section is
261 based on M_1 .

262 *Semiparametric multivariable analysis*

263 The results from fitting M_1 are displayed in Table 4, Figure 4 and Figure 5. Keep-
264 ing the effects of being hypertensive, insulin treatment, frequency of clinical visit,
265 interaction of age by gender, duration of diabetes, $HbA1c \times FBG$ and interaction
266 of total cholesterol level by gender constant, the odds of diabetic retinopathy for a
267 male patient was 3.5 (95% CI:1.14-11.09) times higher than that of female patients.
268 Keeping the effect of other covariates constant, the odds of diabetic retinopathy was
269 significantly higher for the hypertensive patient (adjusted odds ratio (AOR)=38.9,
270 95% CI: 9.85-153.23). The odds of diabetic retinopathy for a patient who used in-
271 sulin treatment was 6.2 (95% CI: 1.81-13.84) times higher than the odds of diabetic
272 retinopathy for a patient who did not use insulin treatment to control their blood
273 glucose level keeping the effect of other covariates constant. Keeping the effect of
274 other covariates constant, the odds of diabetic retinopathy for a patient whose clin-
275 ical visit was every 3 months was 8.7 (95% CI: 2.13-35.9) times higher than the
276 odds of retinopathy for a patient whose clinical visit was every 1 month. Similarly,
277 the odds of diabetic retinopathy was higher for a patient who had follow-up every 6
278 months (AOR=6.7, 95% CI: 1.63-27.41) as compared to a patient who had follow-up
279 every one month keeping the effect of other covariates constant.

280 The result in Table 4 illustrates that holding the effects of other covariates con-
281 stant, there was a significant nonlinear relationship between the log odds of diabetic
282 retinopathy and age of female patients (p -value = 0.0357) with estimated degrees
283 of freedom 3.2. Furthermore, visual inspection of Figure 4(a) shows that the log odds
284 of diabetic retinopathy for female patients increase slightly with age at the beinning,
285 but it shows a gradual decline after the age of 65 years: the confidence band is very
286 wide in this age range, it could be because of a few number of patients older than
287 65 years who experienced diabetic retinopathy. Table 4 also reveals that, duration
288 of diabetes had a significant nonlinear relationship (p -value = 0.0059) with the
289 log odds of diabetic retinopathy. Moreover, according to Figure 4(b), the functional
290 relationship between duration of diabetes and log odds of diabetic retinopathy looks
291 inverted U-shape with estimated degrees of freedom 2.7. However, the confidence
292 band after 30 years of duration of diabetes becomes notably wider, indicating greater
293 variability which may be due to a small number of observations in that interval.
294 As it can be seen in Figure 4(c), the finding of this study also indicates that the

295 relationship between the log odds of diabetic retinopathy and female cholesterol
296 level was initially flat, but a moderate increment in the log odds of DR for a fe-
297 male patient was observed for a total cholesterol level $> 250mg/dL$. Table 4 also
298 shows that there was a significant nonlinear relationship between the log odds of
299 diabetic retinopathy and female cholesterol level ($p - value = 0.0166$) with degrees
300 of freedom 3.6. Similarly, there was a significant nonlinear relationship between the
301 log odds of diabetic retinopathy and HbA1c ($p - value = 0.0020$) with estimated
302 degrees of freedom 2.3. As it can be seen in Figure 4(d), the log odds of diabetic
303 retinopathy has an increasing pattern when the patient HbA1c is between 6%–11%
304 and flat pattern was observed for HbA1c greater than 11%. However, the confidence
305 band at the initial (for HbA1c between (0-4)%) and at the end (for HbA1c $> 11%$)
306 was wide, which may be due to greater variability at these intervals.

307 There was a significant nonlinear relationship between the log odds of diabetic
308 retinopathy and $HbA1c \times FBG$ ($p - value = 0.0500$) with degrees of freedom 3.7
309 (Table 4). The 3D contour plot in Figure 5 indicates that, the risk of diabetic
310 retinopathy increases with increasing HbA1c slowly for the patient with low FBG
311 and the risk was higher for high FBG-HbA1c combinations. Furthermore, the 2D
312 contour plot also shows that the risk of diabetic retinopathy was higher when both
313 FBG and HbA1c were simultaneously high. The darker red region indicates that the
314 risk of being diabetic retinopathy was minimum for the low percentage of HbA1c.
315 Moreover, the combination of $HbA1c \geq 6\%$ and $FBG \geq 150mg/dL$ shows a re-
316 latively high risk of diabetic retinopathy. Generally, the distribution of numerical
317 values (value of linear predictor) on the contour lines in the three regions; dark red
318 (low risk), light red (intermediate risk), and yellow (high risk) of the plots tell the
319 nonlinear relationship between the linear predictor measuring the risk of diabetic
320 retinopathy and $HbA1c \times FBG$.

321 Discussion

322 This study was aimed to identify the contributing factors of diabetic retinopa-
323 thy using data collected from Black Lion Hospital at Addis Ababa, Ethiopia. In
324 the current study, rather than using statistical methods which impose some para-
325 metric assumptions, we focused on the data-driven relationship. The results from
326 applying semiparametric regression analysis on the data showed that the odds of
327 diabetic retinopathy had a significant linear association with gender, hypertension,
328 insulin treatment and frequency of clinical visit. In addition, the log odds of diabetic
329 retinopathy had a significant nonlinear association with the interaction of age by
330 gender (for female patients), duration of diabetes, interaction of cholesterol level by
331 gender (for female patients) and the interaction of HbA1c by FBG.

332 It was observed that being hypertensive was a strong predictive factor of DR. This
333 finding agrees with previous studies. For example, a cross-sectional study conducted
334 by [28] showed that systolic blood pressure was significantly associated with DR.
335 The result of a case-control study [29] in 1000 patients in two groups, patients with
336 retinopathy and patients without retinopathy revealed that those with DR had high

337 systolic blood pressure than patients without DR indicating that systolic blood
338 pressure was one of the contributing factors of DR. Another cross-sectional study
339 [4] using univariate logistic regression analysis reported hypertension as a major
340 risk factor of DR. Tilahun et al. [5], identified hypertension as one of the predictors
341 of diabetic retinopathy. In their study, the odds of being diabetic retinopathy for
342 hypertensive patients appeared 3.39 times higher than that of non-hypertensive
343 patients.

344 According to the current study, insulin treatment was one of the contributing factors
345 of DR. Further, patients who used insulin treatment were more likely at risk than
346 patients who did not use insulin treatment. This result is similar to a study that
347 was based on data from a meta-analysis of seven cohort studies [13]. Their pooled
348 result of the seven-cohort studies showed that insulin use increases the risk of being
349 diabetic retinopathy, where the estimated relative risk was equal to 2.3. One of the
350 other findings of this study was the odds of DR significantly differ for a patient with
351 their number of clinical visits, i.e., patients who visited the diabetic clinic every 3
352 months and 6 months had a higher risk of being diabetic retinopathy than patients
353 who visited the diabetic clinic every one month.

354 In a nonlinear terms of a semiparametric analysis, some interaction terms were
355 incorporated based on scientific literature and exploratory analysis, i.e., age by
356 gender, cholesterol level by gender, and the tensor product or interaction of HbA1c
357 and FBG. As it was discussed in the descriptive statistics section, almost half of the
358 study participants experienced diabetic retinopathy. Therefore, understanding both
359 additive and interaction effects of those socio-demographic and clinical variables is
360 crucial to prevent the progression of DR. The result of this study show that the
361 interaction of age by gender had a significant nonlinear association with being DR,
362 i.e., the log odds of diabetic retinopathy have a significant nonlinear relationship
363 with age of female patients. However, sex and age based stratified analysis showed
364 that the incidence rate of sight-threatening diabetic retinopathy had a decreasing
365 trend for women as compared to men [30]. Despite this, several studies reported
366 the marginal effect of age and gender on being diabetic retinopathy. For example,
367 Hussain et al.[15] show that the risk of diabetic retinopathy was higher for a male
368 patient and a patient with age ≥ 49 years. Tan et al. [18] showed that for a patient
369 with mild DR, older age was associated with lower retinal capillary density, while
370 the result in [31] reveal that sex is not a risk factor for being diabetic retinopathy,
371 but they identified age as a strong predictor of diabetic retinopathy.

372 In the current study, the duration of diabetes since a patient confirmed type II dia-
373 betes was appeared as one of the risk factors of diabetic retinopathy. We identified
374 a nonlinear relationship between duration of diabetes and the log odds of diabetic
375 retinopathy. This result agrees with previous studies [4, 12, 14, 15, 17]. However,
376 these studies used a generalized linear model which can only identify a linear as-
377 sociation between duration of diabetes and linear predictor rather than using a

378 data-driven relationship like a semiparametric model. Furthermore, the interaction
379 between total cholesterol level and gender had a significant nonlinear association
380 with the log odds of diabetic retinopathy. Though, Hanai et al. [32] investigated
381 the progression of diabetic kidney disease and found that those lipid profile pa-
382 rameters are correlated with gender as a predictor of kidney disease progression.
383 Further, Kaewput et al. [33], conducted a nationwide cross-sectional study in Thai-
384 land showing that DR had a significant association with renal function. Therefore,
385 these two studies indirectly revealed that the interaction between the lipid profile
386 of a patient and gender had a significant effect on being diabetic retinopathy.

387 The other interesting finding of our study was the significant nonlinear relationship
388 between interaction $HbA1c \times FBG$ and the log odds of diabetic retinopathy. Despite
389 the nonlinear relationship, a semiparametric model based on the tensor product of
390 HbA1c and FBG suggested that the combination of a high level of HbA1c and a
391 high level of FBG resulted in a higher risk of being diabetic retinopathy. Our study
392 finding agrees with a study that used 10-year follow-up data [20]. Their finding
393 suggested that patients with diabetic retinopathy at the baseline had a high level
394 of FBG and a high level of HbA1c. However, our finding contradicts some of the
395 previous studies. For example, Gimeno-Orna et al. [19] conducted a cohort study
396 with a mean follow-up period of 5.2 years to examine whether FBG variability
397 determines the onset of DR irrespective of HbA1c. Their finding from univariate
398 logistic regression analysis showed that the interaction of mean HbA1c and FBG
399 variability was not a significant risk factor of DR, however, they concluded that
400 FBG variability can determine the onset of diabetic retinopathy. However, several
401 studies showed the marginal effects of FBG and HbA1c on diabetic retinopathy
402 [12, 14, 18].

403 Conclusion

404 This study identified the possible risk factors of diabetic retinopathy based on data
405 obtained from BLH using a semiparametric model. The results from this study indi-
406 cate that clinical variables related to patient characteristics were strong predictors
407 of diabetic retinopathy. Therefore, the results of a semiparametric analysis reveal
408 evidence that being hypertensive, insulin treatment, 3 and 6-months clinical visits
409 were strong predictive factors of diabetic retinopathy. Moreover, duration of dia-
410 betes, interaction of age by gender, and cholesterol level by gender had significant
411 nonlinear relationships with diabetic retinopathy. Additionally, the nonlinear rela-
412 tionship between the interaction $HbA1c \times FBG$ and the linear predictor suggested
413 that the risk of diabetic retinopathy was higher when the value of both HbA1c and
414 FBG high.

415 Based on the findings we recommend that health care professionals should give
416 more attention to the possible effect of clinical variables which can lead a type II
417 diabetic patient to diabetic retinopathy. Since our study was based on one hospital,
418 we recommend that a similar study should be conducted across the country to get
419 more information to improve intervention strategies.

420 Acknowledgements

421 We thank Shibru T, Aga & Boka for providing the data which was originally collected from the Diabetic clinic of
422 Black Lion Hospital, Addis Ababa, Ethiopia for another study [17]. We also thank the National Research Foundation
423 (NRF) of South Africa for the partial scholarship and the University of South Africa (UNISA) for the M & D bursary
424 to top-up the NRF partial scholarship of BEY

425 Funding

426 There was no funding to conduct this research.

427 Abbreviations

428 AIC: Akaike information criteria; BLH: Black lion hospital; CL:Cholesterol level; DD:Duration of diabetes; DM:
429 Diabetes Mellitus; DR: Diabetic retinopathy; FBG: Fasting blood Glucose;FPG:fasting plasma glucose; FCV:
430 Frequency of clinical visits; GCV:generalized cross validation; HbA1c: Hemoglobin A1c; IDF: International diabetes
431 federation; IT: Insulin treatment; NPDR: Non-proliferative diabetic retinopathy; PDR: proliferative diabetic
432 retinopathy; PIRLS: penalized iterative reweighted least squares; REML: Restricted maximum likelihood; VIF:
433 variance inflation factor; UBRE: Unbiased risk estimator.

434 Availability of data and materials

435 The data sets used and/or analysed during the current study are available from the corresponding author on
436 reasonable request.

437 Ethics approval and consent to participate

438 Ethical clearance and approval was obtained from the Institutional Review Board (IRB) of the College of Health
439 Sciences of Addis Ababa University by the data providers [17]. After explaining the purpose and possible benefit of
440 the study, oral and written informed consent was obtained from each patient before starting the procedure. All
441 methods were carried out in accordance with relevant guidelines and regulations/Declaration of Helsinki.

442 Competing interests

443 The authors declare that they have no competing interests.

444 Consent for publication

445 Not applicable

446 Authors' contributions

447 BEY reviewed literature, performed the statistical analyses and drafted the manuscript. LKD supervised and
448 reviewed the findings of data analyses and compilation of the manuscript.

449 Author details

450 ¹Department of Statistics, University of South Africa c/o Christiaan de Wet Road & Pioneer Avenue, Florida 1709,
451 Johannesburg, South Africa. ²Department of Statistics, University of South Africa c/o Christiaan de Wet Road &
452 Pioneer Avenue, Private Bag X6, Florida 1710, Johannesburg, South Africa.

453 References

- 454 1. Obirikorang, Y., Obirikorang, C., Anto, E.O., Acheampong, E., Batu, E.N., Stella, A.D., Constance, O.,
455 Brenya, P.K.: Knowledge of complications of diabetes mellitus among patients visiting the diabetes clinic at
456 sampa government hospital, ghana: a descriptive study. *BMC public health* **16**(1), 1–8 (2016)
- 457 2. Atlas IDF: International Diabetes Federation 9th Edition. (2019). Atlas IDF. <http://www.diabetesatlas.org>
- 458 3. Alam, S., Hasan, M., Neaz, S., Hussain, N., Hossain, M., Rahman, T., *et al.*: Diabetes mellitus: insights from
459 epidemiology, biochemistry, risk factors, diagnosis, complications and comprehensive management. *Diabetology*
460 **2**(2), 36–50 (2021)
- 461 4. Amer, J., Suboh, R., Abualrob, M., Shaheen, A., Abu Shanab, A.: Risk factors associated with diabetic
462 retinopathy: A cross-sectional study within palestinian patients in northern west bank. *Front. Clin. Diabetes*
463 *Healthc.* **2**: 736715. doi: 10.3389/fcdhc (2021)
- 464 5. Tilahun, M., Gobena, T., Dereje, D., Welde, M., Yideg, G.: Prevalence of diabetic retinopathy and its
465 associated factors among diabetic patients at debre markos referral hospital, northwest ethiopia, 2019:
466 Hospital-based cross-sectional study. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy* **13**,
467 2179–2187 (2020)
- 468 6. Boles, S.F., Center, A.A.E.: Diabetic retinopathy: What you should know. US Department of health and
469 Human services, National Eye Institute National Institutes of Health, NIH Publication No: 03-2171 (2020)
- 470 7. Mwangi, N., Gachago, M., Gichangi, M., Gichuhi, S., Githeko, K., Jalango, A., Karimurio, J., Kibachio, J.,
471 Muthami, L., Ngugi, N., *et al.*: Adapting clinical practice guidelines for diabetic retinopathy in kenya: process
472 and outputs. *Implementation science* **13**(1), 1–9 (2018)
- 473 8. Sabanayagam, C., Banu, R., Chee, M.L., Lee, R., Wang, Y.X., Tan, G., Jonas, J.B., Lamoureux, E.L., Cheng,
474 C.-Y., Klein, B.E., *et al.*: Incidence and progression of diabetic retinopathy: a systematic review. *The lancet*
475 *Diabetes & endocrinology* **7**(2), 140–149 (2019)
- 476 9. Flaxman, S.R., Bourne, R.R., Resnikoff, S., Ackland, P., Braithwaite, T., Cicinelli, M.V., Das, A., Jonas, J.B.,
477 Keeffe, J., Kempner, J.H., *et al.*: Global causes of blindness and distance vision impairment 1990–2020: a
478 systematic review and meta-analysis. *The Lancet Global Health* **5**(12), 1221–1234 (2017)
- 479 10. Abebe, N., Kebede, T., Addise, D.: Diabetes in ethiopia 2000–2016 prevalence and related acute and chronic
480 complications; a systematic review. *Afr J Diabetes Med* **25**(2), 7–12 (2017)
- 481 11. Olafsdottir, E., Andersson, D.K., Dedorsson, I., Stefánsson, E.: The prevalence of retinopathy in subjects with
482 and without type 2 diabetes mellitus. *Acta Ophthalmologica* **92**(2), 133–137 (2014)

- 483 12. Ferm, M.L., DeSalvo, D.J., Prichett, L.M., Sickler, J.K., Wolf, R.M., Channa, R.: Clinical and demographic
 484 factors associated with diabetic retinopathy among young patients with diabetes. *JAMA network open* **4**(9),
 485 2126126–2126126 (2021)
- 486 13. Zhao, C., Wang, W., Xu, D., Li, H., Li, M., Wang, F.: Insulin and risk of diabetic retinopathy in patients with
 487 type 2 diabetes mellitus: data from a meta-analysis of seven cohort studies. *Diagnostic pathology* **9**(1), 1–7
 488 (2014)
- 489 14. Tsegaw, A., Alemu, S., Dessie, A., Patterson, C.C., Parry, E.H., Phillips, D.I., Trimble, E.R.: Diabetic
 490 retinopathy in type 2 diabetes mellitus patients attending the diabetic clinic of the university of gondar hospital,
 491 northwest ethiopia. *Journal of Ophthalmology* **2021** (2021)
- 492 15. Hussain, S., Qamar, M.R., Iqbal, M.A., Ahmad, A., Ullah, E.: Risk factors of retinopathy in type 2 diabetes
 493 mellitus at a tertiary care hospital, bahawalpur pakistan. *Pakistan journal of medical sciences* **29**(2), 536 (2013)
- 494 16. Atkin, S.L., Butler, A.E., Hunt, S.C., Kilpatrick, E.S.: The retinopathy-derived hba1c threshold of 6.5% for
 495 type 2 diabetes also captures the risk of diabetic nephropathy in nhanes. *Diabetes, Obesity and Metabolism*
 496 **23**(9), 2109–2115 (2021)
- 497 17. Shibru, T., Aga, F., Boka, A.: Prevalence of diabetic retinopathy and associated factors among type 2 diabetes
 498 patients at tikur. *Journal of Diabetes & Metabolism* (2019)
- 499 18. Tan, F., Chen, Q., Zhuang, X., Wu, C., Qian, Y., Wang, Y., Wang, J., Lu, F., Shen, M., Li, Y.: Associated risk
 500 factors in the early stage of diabetic retinopathy. *Eye and Vision* **6**(1), 1–10 (2019)
- 501 19. Gimeno-Orna, J.A., Castro-Alonso, F.J., Boned-Juliani, B., Lou-Arnal, L.M.: Fasting plasma glucose variability
 502 as a risk factor of retinopathy in type 2 diabetic patients. *Journal of diabetes and its complications* **17**(2),
 503 78–81 (2003)
- 504 20. Massin, P., Lange, C., Tichet, J., Erginay, A., Cailleau, M., Eschwège, E., Balkau, B., an Epidemiological Study
 505 on the Insulin Resistance Syndrome) Study Group, D.D.F., *et al.*: Hemoglobin a1c and fasting plasma glucose
 506 levels as predictors of retinopathy at 10 years: the french desir study. *Archives of ophthalmology* **129**(2),
 507 188–195 (2011)
- 508 21. Coull, B.A., Ruppert, D., Wand, M.: Simple incorporation of interactions into additive models. *Biometrics*
 509 **57**(2), 539–545 (2001)
- 510 22. Chen, H.-F., Ho, C.-A., Li, C.-Y.: Age and sex may significantly interact with diabetes on the risks of
 511 lower-extremity amputation and peripheral revascularization procedures: evidence from a cohort of a
 512 half-million diabetic patients. *Diabetes care* **29**(11), 2409–2414 (2006)
- 513 23. Ghazanfari, Z., Haghdoost, A.A., Alizadeh, S.M., Atapour, J., Zolala, F.: A comparison of hba1c and fasting
 514 blood sugar tests in general population. *International journal of preventive medicine* **1**(3), 187–194 (2010)
- 515 24. Davila, J.R., Sengupta, S.S., Niziol, L.M., Sindal, M.D., Besirli, C.G., Upadhyaya, S., Woodward, M.A.,
 516 Venkatesh, R., Robin, A.L., Grubbs Jr, J., *et al.*: Predictors of photographic quality with a handheld
 517 nonmydriatic fundus camera used for screening of vision-threatening diabetic retinopathy. *Ophthalmologica*
 518 **238**(1-2), 89–99 (2017)
- 519 25. Wood, N.S.: *Generalized Additive Models*. University of Bristol, UK, Boca Raton (2017)
- 520 26. Soley-Bori, M.: *Dealing with missing data: Key assumptions and methods for applied analysis*. Boston
 521 University **23**, 20 (2013)
- 522 27. Allison, P.D.: Multiple imputation for missing data: A cautionary tale. *Sociological methods & research* **28**(3),
 523 301–309 (2000)
- 524 28. Meng, X., Zhang, Y., Kong, Q., Lv, Y., Hu, H., Chen, T., Tang, Z.: Interaction analysis of systolic blood
 525 pressure and glycosylated hemoglobin in diabetic retinopathy: A chinese sample. *Traditional Medicine and*
 526 *Modern Medicine* **2**(03), 119–125 (2019)
- 527 29. Goyal, M., Kamboj, P., Behgal, J., Rathee, S., Lather, T.: Risk factors of diabetic retinopathy in patients with
 528 type 2 diabetes mellitus. *Diabetes Manage* **7**(6), 408–411 (2017)
- 529 30. Lin, J.-C., Shau, W.-Y., Lai, M.-S.: Sex-and age-specific prevalence and incidence rates of sight-threatening
 530 diabetic retinopathy in taiwan. *JAMA ophthalmology* **132**(8), 922–928 (2014)
- 531 31. Magliah, S.F., Bardisi, W., Al Attah, M., Khorsheed, M.M.: The prevalence and risk factors of diabetic
 532 retinopathy in selected primary care centers during the 3-year screening intervals. *Journal of family medicine*
 533 *and primary care* **7**(5), 975–981 (2018)
- 534 32. Hanai, K., Babazono, T., Yoshida, N., Nyumura, I., Toya, K., Hayashi, T., Bouchi, R., Tanaka, N., Ishii, A.,
 535 Iwamoto, Y.: Gender differences in the association between hdl cholesterol and the progression of diabetic
 536 kidney disease in type 2 diabetic patients. *Nephrology Dialysis Transplantation* **27**(3), 1070–1075 (2012)
- 537 33. Kaewput, W., Thongprayoon, C., Rangsin, R., Ruangkanhanasetr, P., Mao, M.A., Cheungpasitporn, W.:
 538 Associations of renal function with diabetic retinopathy and visual impairment in type 2 diabetes: A multicenter
 539 nationwide cross-sectional study. *World journal of nephrology* **8**(2), 33–43 (2019)

540 Figures

Figure 1 A loess fit to the log odds of diabetic retinopathy and continuous predictors separately

Figure 2 Goodness of fit of the imputed observation relative to the observed data for HbA1c and total cholesterol level

541 Tables

Figure 3 A Boxplot for cholesterol level by gender

Figure 4 Estimate of smooths in a semiparametric model.

Figure 5 Estimated effects for the tensor product smooth interaction $HbA1c \times FBG$ in a semiparametric model.

Table 1 Summary statistics of diabetic retinopathy status of type II diabetic patients vs socio-demographic and clinical variables

Characteristics	Levels	Diabetic Retinopathy(DR)		
		Patient with DR, N(%)	Patient without DR, N(%)	Total
Gender	M	47 (24.6)	30 (15.9)	77 (40.5)
	F	51 (26.7)	63 (32.8)	114 (59.5)
Hypertension	No	22 (11.5)	63 (32.9)	85 (44.4)
	Yes	76 (39.8)	30 (15.8)	106 (54.8)
IT	No	58 (30.4)	79 (41.4)	137 (71.7)
	Yes	40 (20.9)	14 (7.3)	54 (28.3)
FCV	every 1 month	14 (7.4)	29 (15.2)	43 (22.6)
	every 3 month	38 (20.0)	34 (17.9)	72 (37.9)
	every 6 month	46 (24.2)	29 (15.3)	75 (39.5)
		mean(sd)	mean(sd)	$n = 191$
Age		58.5(10.1)	56 (10.4)	
DD		15.2(10.9)	9.2 (8.8)	
HbA1c		9.3 (2.8)	7.09 (2.3)	
CL		187.6(56.2)	179.3(41.5)	
FBG		170.9 (66.0)	160.7 (60.6)	

Table 2 Test of nonlinearity for the continuous covariates

nonlinearity test	Models	Resid.Df	resid.Dev	Df	Deviance	$pr(> chi)$
$HbA1c \times FBG$	M_2	158.20	113.21			
$M_2 vs M_1$	M_1	153.43	99.62	4.77	13.59	0.0157*
Age by gender	M_3	158.99	111.61			
$M_3 vs M_1$	M_1	153.43	99.62	5.53	11.98	0.0461*
CL by gender	M_4	168.56	136.83			
$M_4 vs M_1$	M_1	153.43	99.62	15.13	37.20	0.0012*
DD	M_5	158.41	112.64			
$M_5 vs M_1$	M_1	153.43	99.62	4.97	13.02	0.0228*

Table 3 Model comparison using AIC

Models	M_1	M_2	M_3	M_4	M_5
AIC	163.64	169.44	166.52	176.32	168.61

Table 4 Semi parametric estimate of socio-demographic and clinical variables that have a significant effect on DR

predictors	levels	df	$\hat{\beta}$ (se)	p -value	AOR	95%CI
Intercept		1	-4.30 (0.83)	< 0.0001		
Gender	Male	1	1.27 (0.58)	0.0280*	3.5	[1.14, 11.09]
Hypertension	yes	1	3.66 (0.70)	< 0.0001	38.9	[9.85, 153.23]
IT	yes	1	1.84 (0.63)	0.0040*	6.2	[1.81, 13.84]
FCV	every 3 month	1	2.17 (0.73)	0.0020*	8.7	[2.13, 35.9]
	every 6 month	1	1.91 (0.72)	0.0080*	6.7	[1.63, 27.41]
nonlinear Terms						
$f_{gender}(age)$	Female	3.2		0.0357*		
$f_{gender}(age)$	Male	1.0		0.2386		
$f(DD)$		2.7		0.0059*		
$f_{gender}(CL)$	Female	3.6		0.0166*		
$f_{gender}(CL)$	Male	3.7		0.1321		
$f(HbA1c)$		2.3		0.0020*		
$f(FBG)$		1.0		0.2784		
$f(HbA1c, FBG)$		3.7		0.0500*		

Figures








Figure 1

A loess fit to the log odds of diabetic retinopathy and continuous predictors separately




Figure 2

Goodness of fit of the imputed observation relative to the observed data for HbA1c and total cholesterol level






Figure 3


A Boxplot for cholesterol level by gender




(a) Age of female patients



(b) Duration of diabetes



(d) Cholesterol level of female patients



(c) HbA1c of patients

Figure 4

Estimate of smooths in a semiparametric model.




Figure 5

Estimated effects for the tensor product smooth interaction $HbA1c \times FBG$ in a semiparametric model.